EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access

Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia

Deborah A Theodore iD, Amrita D Henneman, Angela Loo, Ryan K Shields iD, Gregory Eschenauer, Magdalena E Sobieszczyk, Christine J Kubin iD

Journal of Antimicrobial Chemotherapy · 01.08.2024 · 79 (8) · 1877-1884

DOI: 10.1093/jac/dkae175 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 04.06.2024. Verfasst von Deborah A Theodore und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Infectious Diseases, New York-Presbyterian Hospital, Columbia University Medical Center, 622 West 168th Street, P…. Hauptthemen laut MEDLINE: Micafungin, Antifungal Agents, Critical Illness, Immunocompromised Host. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, National Institute of Allergy and Infectious Diseases, NIAID NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Candidaemia is associated with poor outcomes including high mortality rates. Controversy remains regarding whether fluconazole or an echinocandin is the optimal choice for initial candidaemia treatment, particularly among high-risk patients such as the immunocompromised or critically ill.

Objectives

To understand optimal initial treatment of candidaemia.

Methods

We conducted a retrospective study of immunocompromised or ICU adult patients with candidaemia from 2010 to 2014. Patients who received ≥3 consecutive days of initial treatment with fluconazole or micafungin were included. The primary outcome was complete response at day 14, defined as clinical improvement and blood culture sterilization. Secondary outcomes included microbiological and clinical success, survival and recurrent candidaemia.

Results

A total of 197 patients were included; 76 received fluconazole and 121 received micafungin. There was no difference in complete response between the fluconazole and micafungin groups (ICU: 38% versus 40%, P = 0.87; immunocompromised: 57% versus 59%, P = 0.80). Secondary outcomes including survival were also similar. In multivariable analysis, among ICU patients, Pitt bacteraemia score < 4 (P = 0.002) and time to antifungal (P = 0.037) were associated with meeting the primary outcome; white blood cell count > 11 cells × 103/µL on day 0 (P < 0.001) and Candida isolated from a non-blood site (P = 0.025) were associated with not meeting the primary outcome. Among immunocompromised patients, white blood cells > 11 × 103/µL (P = 0.003) and Candida isolated from a non-blood site (P = 0.026) were associated with not meeting the primary outcome.

Conclusions

These data suggest that among ICU or immunocompromised patients, severity of illness rather than initial antifungal choice drove clinical outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MicafunginAntifungal AgentsCritical IllnessImmunocompromised HostCandidemiaFluconazoleEchinocandinsHumansMaleRetrospective StudiesFemaleMiddle AgedTreatment OutcomeAgedAdultLipopeptidesSurvival Analysis

Substanzen

MicafunginAntifungal AgentsFluconazoleEchinocandinsLipopeptides

Autor:innen und Institutionen

  • Department of Medicine, Division of Infectious Diseases, New York-Presbyterian Hospital, Columbia University Medical Center, 622 West 168th Street, PH 8W-876, New York, NY 10032, USA.
  • Hofstra Northwell School of Nursing and Physician Assistant Studies, 160 Hofstra University, Hempstead, New York, 11549, USA.
  • Department of Pharmacy, New York-Presbyterian Hospital, 630 W 168th Street, 3rd Floor, New York, NY 10032, USA.
  • Department of Medicine, University of Pittsburgh, Falk Medical Building, Suite 3A, 3601 Fifth Avenue, Pittsburgh, PA 15213, USA.
  • Department of Pharmacy, Michigan Medicine, College of Pharmacy, 428 Church Street, Ann Arbor, MI 48109-1065, USA.

ORCID-Profile: Deborah A Theodore, Ryan K Shields, Christine J Kubin

Förderung

  • NIH HHS
  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • NIH
  • NCI NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health
  • NCI

Zitieren

APA

Theodore, D. A., Henneman, A. D., Loo, A., Shields, R. K., Eschenauer, G., Sobieszczyk, M. E., & Kubin, C. J. (2024). Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia. Journal of Antimicrobial Chemotherapy, 79(8), 1877-1884. https://doi.org/10.1093/jac/dkae175

Vancouver

Theodore DA, Henneman AD, Loo A, Shields RK, Eschenauer G, Sobieszczyk ME, et al. Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia. Journal of Antimicrobial Chemotherapy. 2024;79(8):1877-1884. doi:10.1093/jac/dkae175

BibTeX
@article{Theodore2024,
  author = {Theodore, Deborah A and Henneman, Amrita D and Loo, Angela and Shields, Ryan K and Eschenauer, Gregory and Sobieszczyk, Magdalena E and Kubin, Christine J},
  title = {Initial micafungin treatment does not improve outcomes compared to fluconazole treatment in immunocompromised and critically ill patients with candidaemia},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  volume = {79},
  number = {8},
  pages = {1877--1884},
  doi = {10.1093/jac/dkae175}
}
Kostenlos starten →